Down-regulation of TNF-α via macrophage-targeted RNAi system for the treatment of acute inflammatory sepsis

Lee, Jieun; Son, Wooic; Hong, Juhyeong; Song, Yoonsung; Yang, Chul–Su; Kim, Yong Hee

doi:10.1016/j.jconrel.2021.06.022

Cited by 29 publications

(16 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tocilizumab, a widely studied inhibitor of the IL-6 receptor, blocks the activation of IL-6-mediated signaling pathways, thereby alleviating inflammatory responses in critically ill patients ( 85 ). Several candidate therapies targeting other inflammatory cytokines, such as IL-10, interleukin-2 ( 86 ), and TNF-α ( 87 ), are under investigation. However, the improper use of anti-inflammatory agents may have adverse effects on patients because it may block other relevant signaling pathways mediated by these inflammatory cytokines.…”

Section: Therapies Focusing On Hypercatabolismmentioning

confidence: 99%

Hypercatabolism and Anti-catabolic Therapies in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome

et al. 2022

View full text Add to dashboard Cite

Owing to the development of intensive care units, many patients survive their initial insults but progress to chronic critical illness (CCI). Patients with CCI are characterized by prolonged hospitalization, poor outcomes, and significant long-term mortality. Some of these patients get into a state of persistent low-grade inflammation, suppressed immunity, and ongoing catabolism, which was defined as persistent inflammation, immunosuppression, and catabolism syndrome (PICS) in 2012. Over the past few years, some progress has been made in the treatment of PICS. However, most of the existing studies are about the role of persistent inflammation and suppressed immunity in PICS. As one of the hallmarks of PICS, hypercatabolism has received little research attention. In this review, we explore the potential pathophysiological changes and molecular mechanisms of hypercatabolism and its role in PICS. In addition, we summarize current therapies for improving the hypercatabolic status and recommendations for patients with PICS.

show abstract

Section: Therapies Focusing On Hypercatabolismmentioning

confidence: 99%

Hypercatabolism and Anti-catabolic Therapies in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome

et al. 2022

View full text Add to dashboard Cite

show abstract

“…TNF‐ α , IL‐6, and NF‐ κ B are major pro‐inflammatory cytokines identified as anti‐inflammatory markers that can be released by LPS‐mediated macrophages (Dong et al, 2018 ; Lee et al, 2021 ). Excessive production of pro‐inflammatory cytokines exacerbates a variety of diseases, including allergies, autoimmune disease, and cancer (Benedetto et al, 2019 ; Guo et al, 2019 ).…”

Section: Resultsmentioning

confidence: 99%

Bioactivity‐guided isolation of anti‐inflammatory limonins from Chukrasia tabularis

Shen

Zhang

et al. 2022

Food Science & Nutrition

View full text Add to dashboard Cite

show abstract

“…[54] Peptide-modified nanoparticles have demonstrated prolonged circulation, enhanced cellular uptake and targetability, and/or effective cytosolic drug release to achieve high efficacy both in vitro and in vivo. [55][56][57][58] We developed HO-1 inducer-loaded PLGA nanoparticles with PBP conjugation. PBP is a 9-mer peptide (CKGGRAKDC) with cysteine in both ends and has a selective affinity to prohibitin that is frequently expressed on the membrane of target cells.…”

Section: Discussionmentioning

confidence: 99%

Fatty Liver/Adipose Tissue Dual‐Targeting Nanoparticles with Heme Oxygenase‐1 Inducer for Amelioration of Obesity, Obesity‐Induced Type 2 Diabetes, and Steatohepatitis

Hong

Kim

2022

Advanced Science

Self Cite

View full text Add to dashboard Cite

Persistent uptake of high‐calorie diets induces the storage of excessive lipid in visceral adipose tissue. Lipids secreted from obese adipose tissue are accumulated in peripheral tissues such as the liver, pancreas, and muscle, and impair insulin sensitivity causing type 2 diabetes mellitus (T2DM). Furthermore, the accumulation of inflammatory cytokines and lipids in the liver induces apoptosis and fibrogenesis, and ultimately causes nonalcoholic steatohepatitis (NASH). To modulate obese tissue environments, it is challenged to selectively deliver inducers of heme oxygenase‐1 (HO‐1) to adipose tissue with the aid of a prohibitin targeting drug delivery system. Prohibitin binding peptide (PBP), an oligopeptide targeting prohibitin rich in adipose tissue, is conjugated on the surface of Hemin‐ or CoPP‐loaded poly(lactide‐co‐glycolide) nanoparticles (PBP‐NPs). PBP‐NPs efficiently differentiate lipid storing white adipocytes into energy‐generating brown adipocytes in T2DM and NASH models. In addition, PBP‐NPs are found to target prohibitin overexpressed fatty liver in the NASH model and inhibit hepatic uptake of circulating lipids. Furthermore, PBP‐NPs switch phenotypes of inflammatory macrophages in damaged organs and lower inflammation. Taken together, dual‐targeted induction of HO‐1 in fatty adipose and liver tissues is proven to be a promising therapeutic strategy to ameliorate obesity, insulin resistance, and steatohepatitis by lowering lipids and cytokines.

show abstract

Down-regulation of TNF-α via macrophage-targeted RNAi system for the treatment of acute inflammatory sepsis

Cited by 29 publications

References 34 publications

Hypercatabolism and Anti-catabolic Therapies in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome

Hypercatabolism and Anti-catabolic Therapies in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome

Bioactivity‐guided isolation of anti‐inflammatory limonins from Chukrasia tabularis

Fatty Liver/Adipose Tissue Dual‐Targeting Nanoparticles with Heme Oxygenase‐1 Inducer for Amelioration of Obesity, Obesity‐Induced Type 2 Diabetes, and Steatohepatitis

Contact Info

Product

Resources

About